Damora Therapeutics, Inc.
Close on Oct 19, 2026
- Market cap
- $1.18B
- P/E (TTM)
- 4.8
- Dividend yield
- 0.00%
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 10, 2026 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Jan 6, 2023 | Before market open | – | – | – |
| Q4 FY2020 Ended Dec 31, 2020 | Jan 5, 2021 | During market hours | – | – | – |
Press releases
Announcements Damora Therapeutics filed with the SEC
Damora Announces Redomestication from Delaware to Cayman Islands
Material agreement · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Damora Therapeutics Appoints Biotechnology Leader Jennifer Jarrett as President and Chief Executive Officer; Adds Two Industry Veterans to Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Galecto Announces Name Change to Damora Therapeutics with Mission to Fundamentally Redefine Care for Patients with Blood Disorders
Results of operations · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
January 2026 Company Overview EXHIBIT 99.1 Company Logo
Regulation FD disclosure · EX-99.1 to Form 8-K
Galecto Announces Acquisition of Damora Therapeutics
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
DISCLAIMERS The information contained in this presentation has been
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.1 to Form 8-K
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.2 to Form 8-K
TRANSFORMING TREATMENT of cancer and liver disease with first-in-class small molecule agents Exhibit 99.3
Material agreement · Acquisition or disposition completed · Unregistered share sale · Executive or director change · Charter or bylaw amendment · Regulation FD disclosure · EX-99.3 to Form 8-K
Galecto Presents Updated Clinical Data at ESMO Congress 2023 and Provides Update on Phase 1b/2a GALLANT-1 Trial
Other events · EX-99.1 to Form 8-K
Galecto Announces Plans to Explore Strategic Alternatives
Exit or restructuring costs · Executive or director change · Other events · EX-99.1 to Form 8-K
Galecto Announces Topline Results from Phase 2b GALACTIC-1 Trial of GB0139 for the Treatment of Idiopathic Pulmonary Fibrosis
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First-in-class small molecule antifibrotic and anticancer agents January 2023 Exhibit 99.1
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Galecto to Present Topline Data from GULLIVER-2 Clinical Trial Showing GB1211 Reduced Signs of Liver Impairment at AASLD’s The Liver Meeting ® 2022
Regulation FD disclosure · EX-99.1 to Form 8-K
GB2064 Shows Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis, Validating LOXL2 as a Clinical Fibrosis Target
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
First-in-class small-molecule anti-fibrotic and anti-cancer agents January 2022 Exhibit 99.1
Regulation FD disclosure · EX-99.1 to Form 8-K